跳到正文
EMA 官方医药监管信息·精选AI 评分61

EMA CVMP 发布兽药使用者安全指南第2版草案(EMEA/CVMP/543/03-Rev.2)并征求意见

Draft guideline on user safety for pharmaceutical veterinary medicinal products - Revision 2

AI 导读

EMA 兽药委员会(CVMP)发布兽药使用者安全指南第2版草案(EMEA/CVMP/543/03-Rev.2)公开征求意见,评论截止2026年12月31日。草案替代 Rev.1,更新引用 Regulation (EU) 2019/6 及其附录II,并纳入 3Rs 与替代试验方法。

推荐理由

材料为兽药使用者安全指南第2版草案,列出风险评估流程章节与征求意见安排,可供读者定位需要核对的评估步骤。

正文 · 原文

PDF 文字版;图形和原始排版请参阅官方 PDF。

第 1 页

1   18 September 2026
2   EMEA/CVMP/543/03-Rev.2
3   Committee for medicinal products for veterinary use (CVMP)




4   Guideline on user safety for pharmaceutical veterinary
5   medicinal products
6   Draft



      Draft agreed by Safety Working Party (SWP-V)                                                          10 December 2025

      Adopted by CVMP for release for consultation                                                        10 September 2026

      Start of public consultation                                                                        18 September 2026

      End of consultation (deadline for comments)                                                           31 December 2026

7
      Comments should be provided using this template

8
      Keywords                              User safety
9

10   This revision replaces the previous version of the CVMP guideline on user safety for pharmaceutical
11   veterinary medicinal products (EMEA/CVMP/543/03-Rev.1).




     Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
     Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
     Send us a question Go to www.ema.europa.eu/contact     Telephone +31 (0)88 781 6000       An agency of the European Union

     © European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.

第 2 页

12   Guideline on user safety for pharmaceutical veterinary
13   medicinal products
14   Table of contents
15   Executive summary ..................................................................................... 3
16   1. Introduction (background) ...................................................................... 3
17   2. Scope....................................................................................................... 3
18   3. Legal basis .............................................................................................. 4
19   4. Principles of the assessment ................................................................... 5
20   5. User risk assessment ............................................................................... 5
21   5.1. Hazard identification and characterisation................................................................ 5
22   5.1.1. Toxicity data on active substance(s) .................................................................... 6
23   5.1.2. Toxicity data on the formulation .......................................................................... 8
24   5.1.3. Conduct of toxicity studies .................................................................................. 8
25   5.2. Exposure assessment ........................................................................................... 9
26   5.2.1. Precise identification of the product, defining the properties of the veterinary
27   medicinal product ....................................................................................................... 9
28   5.2.2. Exposure scenarios ............................................................................................ 9
29   5.2.3. Characterisation of the population exposed, the type of user................................. 10
30   5.2.4. Defining the routes of exposure ......................................................................... 10
31   5.2.5. Defining the components of a product to which the user is exposed ....................... 10
32   5.2.6. Estimating the magnitude, duration and frequency of exposure ............................. 11
33   5.3. Risk characterisation ........................................................................................... 12
34   5.3.1. Qualitative risk characterisation......................................................................... 12
35   5.3.2. Quantitative risk characterisation ...................................................................... 12
36   5.4. Risk management .............................................................................................. 14
37   5.5. Risk communication ............................................................................................ 15

38   Definitions ................................................................................................. 17
39   References ................................................................................................ 20
40   Abbreviations ............................................................................................ 20
41   Annex 1 ..................................................................................................... 21
42   Example 1: URA based on a qualitative risk characterisation .......................................... 21
43   Example 2: URA based on a quantitative risk characterisation ........................................ 23

44   Annex 2 ..................................................................................................... 26
45   Template for a user risk assessment ........................................................................... 26




     Guideline on user safety for pharmaceutical veterinary medicinal products
     EMEA/CVMP/543/03-Rev.2                                                                                           Page 2/26

第 3 页

46    Executive summary
47    The guideline on user safety for pharmaceutical veterinary medicinal products (VMPs) provides
48    guidance and advice on the procedure for user risk assessments. The guideline initially came into effect
49    in 2005 and was revised in 2010. The guideline has been further revised to reference current
50    legislation (i.e. Regulation (EU) 2019/6 and its Annex II), and to take into account updated definitions.
51    Opportunities for the implementation of the 3Rs (replacement, reduction, refinement) and alternative
52    testing approaches have also been included. This guideline has been updated to reflect the approaches
53    common to all pharmaceutical veterinary medicinal products. Additional guidance on the use of
54    uncertainty factors as they relate to the margin of exposure and consideration of the adequacy of risk
55    mitigation measures has also been included.


56    1. Introduction (background)
57    Marketing authorisations for veterinary medicinal products in the European Union are granted in
58    accordance with Regulation (EU) 2019/6. This legislation requires that applications for VMPs contain
59    safety documentation. Annex II of Regulation (EU) 2019/6 states that “the safety documentation shall
60    be adequate for assessment of (b) the potential risks which may result from the exposure of human
61    beings to the veterinary medicinal product, for example, during its administration to the animal.”
62    Furthermore, it provides that, with regard to user safety “This section shall include an assessment of
63    the effects found in Part II.3A to II.3A4 (or Part IIIa.3a to IIIa.3A4) and relate this to the type and
64    extent of human exposure to the product with a view to formulating appropriate user warnings and
65    other risk management measures.”

66    The legislation does not provide specific guidance on data requirements and assessment methods to be
67    used to identify the risks, or on the measures for risk reduction for users. This guideline presents
68    guidance and advice on user safety and the conduct of user risk assessments.


69         2. Scope
70    The objective of this guideline is:

71•   to provide guidance and advice on user risk assessments.

72    While this guideline is primarily intended for pharmaceutical VMPs, it can also be applied to biologicals
73    other than immunologicals. For applications for immunological VMPs, guidance can be found in the
74    ‘Guideline on user safety for immunological veterinary medicinal products’
75    (EMA/CVMP/IWP/54533/2006 Rev.1).

76    The guideline applies to all Marketing Authorisation (MA) applications for pharmaceutical VMPs. This
77    also includes applications to vary the MA where there is an impact on user safety.

78    Some types of post-authorisation changes warrant a reassessment of user safety, for example:

79•   Changes to the clinical use of the authorised products resulting in a significant increase in the handled
80    dose, including the duration of use;
81•   The identification of new information impacting on the assessment of the risks of the VMP, such as new
82    hazard data on the ingredients of a product including new excipients;
83•   A change of packaging material resulting in an increased potential for user exposure, especially taking
84    into account the volumes that may be spilled and the child-resistant properties.

85    For a generic product, a full user risk assessment would not normally be expected, as the conclusion
86    on user safety of the product and appropriate user safety warnings should reflect the user safety


      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                            Page 3/26

第 4 页

87   evaluation undertaken for the reference product. However, in accordance with Annex II of Regulation
88   (EU) 2019/6, section IV.1.2 (e), where there are aspects of the generic product that differ from the
89   reference product (e.g. composition in excipients), then the impact of these differences on user safety
90   should be addressed. For topical VMPs, for example, a difference (qualitative and quantitative) in
91   excipients may result in different exposure of the pet owner due to a possible change in dermal
92   absorption and/or the amount of VMP that is removed from the animal’s fur when stroked. In that
93   situation, the outcome of the risk assessment and subsequent risk mitigation measures may differ
94   from that of the reference product. This might also be the case when salts, esters, ethers, isomers and
95   mixtures of isomers, complexes or derivatives of the active substance of the reference VMP (i.e.
96   differences in the active substance) significantly affect safety, as referred to in Art 18(2) of Regulation
97   (EU) 2019/6. Also, where a difference in product packaging has been identified, the applicant must
98   justify why the risk to users remains unchanged for the generic product or implement appropriate risk
99   management measures (e.g., with respect to the need for a child-resistant closure).

100   The above is also applicable for hybrid products. In addition, in accordance with sections IV.2.2. and
101   IV.2.5 of Annex II of Regulation (EU) 2019/6, depending on the hybrid product, new data may be
102   required to support safety of the hybrid product.

103   In general, this guideline is not intended to be applied retrospectively (i.e. to products marketed prior
104   to the adoption of this guideline). However, according to article 58(4) of Regulation (EU) 2019/6 on the
105   responsibilities of the marketing authorisation holders, “The marketing authorisation holder shall
106   ensure that the summary of product characteristics, package leaflet and labelling is kept up to date
107   with current scientific knowledge.”

108   For applications for Marketing Authorisation for topical products, the guideline should be used in
109   conjunction with the ‘Guideline on user safety of topically administered veterinary medicinal products’
110   (EMA/CVMP/SWP/721059/2014).

111   For the assessment of user safety, the user is defined as any person that may come into contact with
112   the VMP or its components before its application to the animal (e.g. during storage), during its
113   application, and after its application (e.g. through contact with the treated animals).

114   The assessment of the user safety of a VMP should address the exposure situations resulting from the
115   normal conditions of use and from foreseeable accidents (including accidental ingestion by children and
116   accidental self-injection). It does not include exposure situations resulting from intentional misuse.

117   The guideline does not address occupational safety during the manufacture of veterinary medicinal
118   products but covers the incorporation of premixes (VMPs) into feed. Although Regulation (EU) 2019/6
119   does not apply to medicated feed, the user safety requirements are relevant to both the VMP and the
120   resulting medicated feed. Accordingly, this guideline may also be used to address the user safety
121   aspects of the medicated feed.


122   3. Legal basis
123   Requirements for safety testing for a marketing authorisation application are laid down in Regulation
124   (EU) 2019/6 of the European Parliament and of the Council.

125   This guideline concerns the application of the requirements of Annex II to Regulation (EU) 2019/6,
126   mentioned in Part 3 of Sections II for VMP other than biological VMP, and IIIa for biological VMP other
127   than immunological VMP, User safety shall “…include an assessment of the effects found in Part II.3A
128   to II.3.A4 (or Part IIIa.3a to IIIa.3A4) and relate this to the type and extent of human exposure to the
129   product with a view to formulating appropriate user warnings and other risk management measures.”
130   Moreover, “User safety shall be addressed in accordance with CVMP guidelines.”


      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                             Page 4/26

第 5 页

131    It should be noted that for an excipient used for the first time in a VMP or by a new route of
132    administration, the same data requirements as for the active substance should apply (see II.3A (3)
133    and IIIa.3A (3) of Regulation (EU) 2019/6).

134    All animal experiments should be conducted taking into account section I.1.7 of Annex II of Regulation
135    (EU) 2019/6 and the 3Rs principles (replacement, reduction and refinement), notwithstanding the
136    place of conduct of the experiments. Alternatives to in vivo test methods should be employed
137    whenever possible.


138    4. Principles of the assessment
139    A risk analysis presented for the VMP for users handling and administering it, or who become exposed
140    via contact with treated animals, should be provided and should address the following aspects:

141•   Hazard identification and characterisation. An appraisal of the inherent toxicity of the VMP and
142    identification of the most relevant toxicological reference values (TRVs);

143•   Exposure assessment. An appraisal of how and when the user may be exposed to the VMP –
144    identification of user groups, relevant exposure scenarios and estimation of the user exposure for each
145    scenario;

146•   Risk characterisation. The assessment of the level of risk by establishing margins of exposure (MOEs)
147    through comparison of the exposure levels with the toxicological reference values, and the assessment
148    of local effects;

149•   Risk management and communication. The proposal of appropriate and practical risk mitigation
150    measures, where relevant.

151    An appraisal of the inherent toxicity and any other harmful physico-chemical effects, such as
152    flammability, dustiness and volatility of the active substance and the formulation, should be conducted.
153    The hazards should be identified and characterised using appropriate data from toxicity tests or
154    published literature regarding relevant endpoints for local and systemic toxicity, taking into account
155    the route, duration, and frequency of anticipated exposure. The studies conducted should be relevant
156    to the route of exposure, for example, if only dermal exposure is anticipated, no information regarding
157    inhalation toxicity is deemed necessary.

158    An appraisal of the exposure of the user and any others who may come into contact with the VMP,
159    should be conducted. All possible exposure scenarios should be considered; these should include route
160    and level of exposure, frequency of use and amount used. The users, including all people possibly
161    exposed to the VMP, should be identified.

162    The procedure for the risk characterisation consists of comparing the exposure levels to which the user
163    is exposed or is likely to be exposed with those at which no adverse effects are expected to occur.
164    When there is a potential risk for the user, appropriate measures for risk reduction should be proposed
165    and evaluated.


166    5. User risk assessment

167    5.1. Hazard identification and characterisation

168    Generally, most of the toxicity data required to perform a hazard identification are already included in
169    the Marketing Authorisation dossier (Part IIIA Safety Documentation). The overall assessment of the
170    data allows a conclusion to be drawn on whether available data are sufficient for use in the risk
171    assessment. The potential need for additional studies depends on the exposure and any identified data

       Guideline on user safety for pharmaceutical veterinary medicinal products
       EMEA/CVMP/543/03-Rev.2                                                                             Page 5/26

第 6 页

172   gaps, and in some cases, the nature of the substances may indicate the need to focus on specific
173   endpoints of toxicity or pharmacology. The purpose is to derive toxicological reference values (TRV)
174   with respect to the identified exposure scenarios. If appropriate TRVs cannot be established for a
175   particular route of exposure or by route-to-route extrapolation, new studies should be performed to
176   generate route specific data. These new studies may be in vivo or based on scientifically valid
177   alternative methods, however, a stepwise approach should be employed, with animal testing used only
178   where absolutely necessary. The results of all provided studies should be assessed in order to identify
179   the potential adverse health effects that can be caused by exposure to the substance(s) of concern.
180   This applies to the active substance(s) as well as new excipients, and may also apply to other
181   excipients which cause concern (e.g. an excipient which is known to be harmful).

182   5.1.1. Toxicity data on active substance(s)

183   The toxicity data presented in the dossier relating to the active substance may be derived from animal
184   or non-animal toxicity studies or from published literature. These studies should ideally be designed
185   and selected to investigate the effects of single doses and repeated doses, and to consider endpoints
186   for effects on reproductive performance, fertility, developmental toxicity, genotoxicity and
187   carcinogenicity. In line with the 3Rs, it is recommended to derive information on single dose toxicity
188   from existing studies, e.g. from repeated dose or developmental toxicity studies. Depending on the
189   type of product, special studies may have been conducted, for example to investigate inhalation
190   toxicity, sensitisation potential, skin and eye irritation, or immunotoxicity or neurotoxicity.

191   Whenever possible, dose-response relationships should be identified in order to derive a TRV, i.e. the
192   no observed adverse effect level (NOAEL), or, if this is not possible, the lowest observed adverse effect
193   level (LOAEL). The use of the benchmark dose lower confidence limit (BMDL) is also acceptable as a
194   point of departure. Using the BMDL as a point of departure has the advantage that it provides a
195   quantitative dose-response assessment taking into account the variability of the data and the slope of
196   the dose-response curve.

197   It is considered that the use of LD50 values as TRVs is not appropriate, as at this dose adverse effects
198   already occur. Furthermore, LD50 studies generally provide only limited toxicological information and
199   are therefore, not suitable for deriving NO(A)ELs.

200   Target animal safety studies should normally not be used for the derivation of TRVs as they are not
201   designed for this purpose, but for observing adverse effects at the therapeutic dose (and overdoses) in
202   the target animal. However, these studies may in exceptional cases contain the most sensitive
203   endpoint and might then be employed for the derivation of TRVs. Similarly, pharmacovigilance data
204   can provide additional information for a substance or product, though they cannot be used to define a
205   NO(A)EL.

206   TRVs are established for all relevant toxicological endpoints (critical effects), and are specific to a
207   substance, duration of exposure (acute, sub-chronic or chronic) and route of exposure (oral, dermal
208   and inhalation). Pharmacological effects should also be considered, i.e. when the dose associated with
209   pharmacological effect is below the toxicological TRV. The appropriate TRV for quantitative risk
210   assessment is to be selected considering the route of user exposure, the duration of user exposure and
211   the substance concerned. If more than one NOAEL is available for a given exposure scenario, the
212   choice of the NOAEL to be used as the TRV should be fully justified.

213   In the context of a risk assessment, these TRVs should be compared to exposure levels of the
214   substance(s) of concern that correspond to similar durations and routes of exposure. In the absence of
215   a TRV for a specific route of exposure (e.g. dermal), the use of a TRV defined from an oral study
216   should be considered using route-to-route extrapolation with appropriate adjustments to address


      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                               Page 6/26

第 7 页

217   differences in bioavailability. Further information on route-to-route extrapolation can be found in the
218   ‘Guideline on user safety of topically administered veterinary medicinal products’
219   (EMA/CVMP/SWP/721059/2014). Even if the TRV is based on the most sensitive critical effect, other
220   effects may also be taken into consideration (e.g. reproductive or developmental effects) in order to
221   focus the user safety risk assessment on specific scenarios or user groups. For instance, any possible
222   adverse effect on the pregnant female and the development of the embryo and foetus, or on male and
223   female fertility, should be assessed using an appropriate TRV.

224   In the case of developmental toxicity, Annex II to Regulation (EU) 2019/6 states that ‘For the
225   evaluation of user safety, standard developmental toxicity testing in accordance with standard tests
226   based on established guidance (including VICH GL32 and OECD tests) shall be performed in all cases
227   where significant user exposure may be expected.’ In this context, significant user exposure is
228   considered to occur where systemic exposure to the substance is possible. Significant exposure is not
229   expected to occur where it can be demonstrated that absorption following oral ingestion or from sites
230   of local exposure (e.g. skin or eyes) will lead to negligible systemic exposure (e.g. substances that are
231   not absorbed). In addition to the absorption properties of the substance, characteristics of the product
232   formulation can result in negligible exposure (e.g. coated or non-divisible tablets, as it is expected that
233   these forms leave minimal to no residues on the skin). Where standard developmental toxicity tests
234   are not provided, based on a claim of negligible exposure, adequate justification and supporting data
235   for the omission of such studies should be provided.

236   Where systemic exposure cannot be avoided following exposure to the veterinary medicinal product,
237   significant exposure is assumed. In that case, the risk to the pregnant user should be assessed. In
238   order to avoid unnecessary animal testing this should be done by employing first, all existing
239   information on developmental toxicity in a weight of evidence approach that supports a quantitative
240   risk assessment, i.e. allows for the derivation of a safe dose for the user. Such information can include,
241   for example, studies from published literature, data derived from in vitro methods, observations in
242   humans, etc. If no adequate conclusion on a safe dose or a mitigable risk for pregnant women can be
243   drawn based on available information, standard developmental toxicity tests should be conducted.

244   If the active substance has been used in human medicines, then any available data, including company
245   data as well as data in the published literature, relating to observations and adverse reactions in
246   humans should be submitted in the dossier. If generated experimentally in humans, the applicant
247   should confirm that the studies were conducted in accordance with recognised ethical standards 1.
248   Available human data can also be considered for the derivation of TRVs if these studies are relevant
249   from a scientific point of view and can be employed for quantitative risk assessment. However, for any
250   given substance, the accepted therapeutic dose used in human medicine does not imply an absence of
251   risk and, therefore, is generally not acceptable as a TRV.

252   In the case of 'fixed combination products', containing two or more active substances, data on
253   individual active substances should be considered as the basis. However, it may also be necessary to
254   provide toxicological data for the combination if there are interactions between the active substances
255   such as synergistic effects, in accordance with the EMA ‘Guideline on pharmaceutical fixed combination
256   products’ (EMA/CVMP/83804/2005).

257   Studies reported in the scientific literature may be accepted if they contain a sufficient amount of data
258   and sufficient details to allow an independent assessment by the competent authority (see also section
259   II.3(2) of Regulation (EU) 2019/6). Information from EPMARs can be summarised; in that case there is




      1 If data are provided from studies conducted in humans it should be confirmed that the study was conducted in

      accordance with the ethical principles that have their origins in the Declaration of Helsinki.

      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                                   Page 7/26

第 8 页

260   no need to submit studies already evaluated as part of the MRL evaluation, only new studies should be
261   provided.

262   5.1.2. Toxicity data on the formulation

263   The systemic effects are usually assessed only for the active substance(s). However, when there is a
264   specific concern with regard to systemic effects due to the presence of one or more of the excipients in
265   the VMP (e.g. an excipient which is known to be harmful), it may be necessary to assess the systemic
266   toxicity of these excipients or of the formulated product.

267   For toxicity studies on local effects, Annex II to Regulation (EU) 2019/6 states that “For products for
268   which there may be exposure to skin and eyes, irritation and sensitisation studies shall be provided.”
269   In the case of pharmaceutical VMPs (Section II.3A.4.1), “those studies should be conducted with the
270   final formulation”, whereas for biological VMPs other than immunological VMPs (Section III.3A.4.1),
271   “those studies should usually be conducted with the final formulation.” New data should be generated
272   using in vitro methods as described in current OECD test guidelines (see 5.1.3.), e.g. skin
273   irritation/corrosion test methods in OECD Test Guidelines 430, 431, 435, 439; eye irritation/corrosion
274   test methods in OECD Test Guidelines 437, 438, 460, 467, 491, 492, 492B, 494, 496; and skin
275   sensitisation OECD Test Guidelines 442C, 442D, 442E, 497. However, many of these test methods
276   have not been validated for mixtures. In that case, it would be acceptable to test the single substances
277   of the VMP using these in vitro methods instead of the final product formulation. Nonetheless, full
278   consideration should be given to possible interaction between active substances and/or excipients.
279   Additionally, in the interest of reducing testing requirements in animals, if there are only historical data
280   or published literature on the ingredients of the formulation, the potential effects of a VMP can be
281   deduced from these data. If the test article is irritating to the skin, it is assumed that it is also irritating
282   to the eyes.

283   5.1.3. Conduct of toxicity studies

284   If toxicity tests are conducted to address any identified gaps in the dataset, they should be carried out
285   in accordance with VICH/OECD guidance and current methodology and, where advised, should follow a
286   stepwise approach (e.g. studies to evaluate genotoxicity (VICH GL23)). Validated 2 or qualified 3
287   alternative test methods should be employed whenever possible. Information on opportunities for
288   limiting animal use in current testing requirements is provided in the “Reflection paper on providing an
289   overview of the current regulatory testing requirements for veterinary medicinal products and
290   opportunities for implementation of the 3Rs” (EMA/CHMP/CVMP/3Rs/164002/2016). This document is
291   updated regularly and the most recent version should be consulted for reference.

292   It is noted that for some endpoints, standardised test methods are currently not available, in particular
293   for parenteral toxicity (e.g. from injectable VMPs) and respiratory sensitisation. However, for
294   parenteral toxicity, target animal safety studies may provide relevant information on local and
295   systemic effects following this route of exposure. Data on skin sensitisation may serve as a surrogate
296   for respiratory sensitisation, in the absence of appropriate methods.




      2 Validated according to OECD guidance document 34 (https://www.oecd.org/en/publications/guidance-document-on-the-

      validation-and-international-acceptance-of-new-or-updated-test-methods-for-hazard-assessment_e1f1244b-en.html)
      3 Qualified according to EMA guideline EMA/CHMP/CVMP/JEG-3Rs/450091/2012

      (https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-principles-regulatory-acceptance-3rs-
      replacement-reduction-refinement-testing-approaches_en.pdf)

      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                                     Page 8/26

第 9 页

297    5.2. Exposure assessment

298    Exposure is the contact between an agent and a target, i.e. of a VMP with a user. Exposure assessment
299    is the process that involves estimating the magnitude, frequency, and duration of exposure to a VMP
300    for a specific substance, route of exposure and user.

301    The process includes:

302•   Precise identification of the product, defining the properties of the VMP (5.2.1)

303•   Exposure scenarios (5.2.2)

304•   Characterisation of the population exposed, including the type of user (5.2.3)

305•   Defining the routes of exposure (5.2.4)

306•   Defining the components of the product to which the user is exposed (5.2.5)

307•   Estimating the magnitude, duration and frequency of exposure (5.2.6)

308    The elements are further discussed below.


309    5.2.1. Precise identification of the product, defining the properties of the
310    veterinary medicinal product

311    The first step in the exposure assessment is to consider the properties of the VMP. This should cover
312    the following items:

313•   the pharmaceutical form

314•   relevant physico-chemical properties

315•   the presentation (quantity available to the user, packaging)

316•   the method of use, including the route of administration and any dosing equipment to be used

317    5.2.2. Exposure scenarios

318    The next step in the exposure assessment is to identify the exposure scenarios, starting with tasks
319    and/or situations that may lead to exposure of humans. Different phases before, during and after
320    administration of the product to the animal(s) should be considered.

321    Table 1 illustrates different tasks and situations that may be relevant for a VMP. It should be noted
322    that these are examples only and that there are other situations that may be considered depending on
323    the VMP.

324    Table 1. Some examples of tasks and situations that may lead to exposure

        Pre-administration phase                    Administration phase              Post-administration phase

        Storage                                     Opening or accessing the          Cleaning equipment &
                                                    product: e.g., taking product     preparation areas
                                                    out of packaging                  Disposal activities: e.g.,
                                                    Mixing and/or diluting of         disposal of packaging,
                                                    concentrates: e.g., mixing with   equipment & surplus product
                                                    feed & water                      Handling treated animals
                                                    Loading application apparatus     including stroking
                                                    or system: e.g., dosing gun


       Guideline on user safety for pharmaceutical veterinary medicinal products
       EMEA/CVMP/543/03-Rev.2                                                                                      Page 9/26

第 10 页

                                                   Administration to the animal(s):
                                                   e.g., holding/restraining animal
                                                   for treatment


325   For products containing particularly hazardous substances (e.g. DNA reactive/cytotoxic products),
326   post-administration exposure to excreta (e.g. vomit, saliva) should also be considered (see the
327   Guideline on dossier requirements for anticancer medicinal products for dogs and cats
328   (EMA/CVMP/28510/2008) for further guidance).

329   Once the tasks and situations that lead to exposure are identified, the exposure for each task/situation
330   should be further characterised. See the subsections below.

331   5.2.3. Characterisation of the population exposed, the type of user

332   It is important to clearly identify the different types of users of the product and to include all users that
333   might come into contact with the VMP, some of whom may not necessarily be administering the VMP,
334   but may be indirectly exposed to the VMP.

335   Some examples of people who are users are: a veterinarian, a veterinarian’s assistant, a farmer, a
336   bystander, a breeder, a pet-owner, a person living in the same building (e.g. child), a canine
337   beautician or a sheep shearer. With regard to medicated premixes, the user of the VMP will be the
338   individual incorporating the premix into a medicated feed or intermediate product. In addition,
339   although Regulation (EU) 2019/6 does not apply to medicated feed, it is recommended that the
340   exposure scenario for the end-user, i.e. the handler of the medicated feed, including young children
341   who may have access to the medicated feed, be considered when assessing user safety.

342   When a VMP is kept in the home or in places where children may be present (e.g. horse stables),
343   children should be identified as users.

344   5.2.4. Defining the routes of exposure

345   The routes of exposure should be specified for each exposure scenario. The routes of exposure will
346   generally depend on the type of product, the pharmaceutical form, and the dosing equipment (if any).
347   The routes to be considered are dermal, inhalation, ocular, and parenteral (accidental self-injection),
348   with oral exposure often assessed.

349   Oral exposure should be considered for children. The inclusion of the warning “keep out of the sight
350   and reach of children” on the label and package leaflet of products is a standard phrase for all VMPs,
351   regardless of whether a risk is identified or not. However, the risks of oral ingestion should always be
352   considered for products for which children have been identified as users (see section 5.3.2). If the
353   toxicity data and subsequent risk characterisation suggest that there may be a concern after accidental
354   ingestion, minimising exposure to children should be addressed. This might be achieved by inclusion of
355   specific user safety warnings with respect to the storage of a VMP (e.g. storage of unused tablet parts
356   in the blister or not to leave a filled syringe unattended), or by considering child-resistant packaging.

357   For adult users, oral exposure due to hand-to-mouth contact should be considered when dermal
358   exposure is likely due to handling the product or from stroking a pet when there are residues on the
359   fur. The non-respirable fraction of an inhalation exposure is also considered to be swallowed.

360   5.2.5. Defining the components of a product to which the user is exposed

361   Users can be exposed to:


      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                             Page 10/26

第 11 页

362•   the whole product (e.g. a powder, a concentrate), including its active and inactive ingredients;

363•   certain components of the product (e.g. an active substance released from a collar);

364•   solutions or dilutions of a product (e.g. medicated drinking water; spray mists from dosing equipment).

365    For each exposure scenario, it should be specified to what (e.g. whole product, components, dilution)
366    the user is exposed.

367    5.2.6. Estimating the magnitude, duration and frequency of exposure

368    Information on the magnitude, duration and frequency of exposure is needed in order to estimate the
369    user exposure level to be used in the quantitative risk characterisation.

370    Although all situations that lead to exposure can be considered, it will not mean that each of these
371    situations will occur every time the product is used. For example, “accidental self-injection” is an
372    exposure situation, but there is a low probability that this event will actually happen when the product
373    is used, i.e. it is a rare event and has a very low frequency. However, when applying a medicated
374    shampoo to a dog, skin contact with the shampoo during application will occur almost every time it is
375    used; dermal exposure is therefore considered to have a high frequency. Dermal and hand-to-mouth
376    exposure from coated or non-divisible tablets is generally considered to be negligible.

377    The magnitude, duration and frequency of exposure determine the quantitative part of an exposure
378    scenario.

379    The exposure level should be estimated by the applicant on the basis of experience with the product or
380    comparable types of products, taking into account the use of the product by all users, and the pattern
381    of use (single use or repeated (consecutive or interval) administration).

382    The magnitude of exposure is often determined by parameters like the dose or volume handled,
383    concentration (e.g. in solutions or in air), release rate (e.g. from a collar or from a spray apparatus),
384    vapour pressure, particle size, droplet size and spray pattern; from these data the external dose for a
385    user is estimated.

386    To estimate the internal dose, the pharmacokinetic properties (in particular data on absorption and
387    bioavailability) of the relevant compounds should be taken into account.

388    The estimation of the exposure levels may include measured data as well as model calculations. Any
389    assumptions made in the exposure assessment should be clearly indicated and justification should be
390    given, and the input data or default values used for the calculations should be documented.

391    When considering the exposure level per kg of bodyweight, a default bodyweight of 60 kg is used by
392    CVMP for adults. For children, the default bodyweight is 12.5 kg, considered to represent a child aged
393    2 to <3 years old who is active in exploring their environment. This value is derived from a study in
394    the Dutch population (considered to be representative for the European population) and corresponds to
395    the 25th percentile of the Dutch population; 12.4 kg (RIVM report 090013003/2014), rounded up to
396    12.5 kg.

397    Examples of exposure parameters that can influence the magnitude of exposure, include surface areas
398    of body parts, respiratory rates, size and volume of a room, dip tank volume, and ventilation rates of
399    rooms.

400    Irrespective of the method used, the prediction of the exposure levels should describe a reasonably
401    worst-case situation.




       Guideline on user safety for pharmaceutical veterinary medicinal products
       EMEA/CVMP/543/03-Rev.2                                                                            Page 11/26

第 12 页

402    If more than one route of exposure is involved in a single situation (e.g. dermal and oral exposure due
403    to hand-to-mouth contact), the total systemic exposure (sum of routes) should be calculated. In some
404    cases, the same compound or product is to be used to treat an animal and its environment (e.g. a flea
405    powder). When it is foreseeable that animal beddings, premises etc. will be treated as well, an
406    assessment of aggregate exposure from both uses should be made. Similarly, if several animals are to
407    be treated at the same time (e.g. a flock of sheep), the estimation of the exposure level should be
408    made for multiple applications.

409    5.3. Risk characterisation

410    5.3.1. Qualitative risk characterisation

411    For a number of toxicological endpoints, the methods for testing provide qualitative results. This is in
412    particular the case for certain local effects, for example, sensitisation or irritation. For these effects, no
413    information on dose-response relationships will be available and, hence, thresholds remain unknown.
414    Consequently, no quantitative risk assessment can be made for the anticipated exposure levels.
415    Instead, only a hazard identification can be made.

416    Although a quantitative risk characterisation cannot be made for these endpoints, the risk may be
417    qualitatively characterised, taking into account the likelihood that such an effect will occur on the basis
418    of the concentration in the VMP and/or exposure information. Whenever possible, available information
419    on the severity of an effect at the anticipated exposure levels should be taken into account as well. If
420    such information is not available, it should be assumed that the effects will occur at any exposure
421    level.

422    In addition, risks to the user related to the physico-chemical properties should be identified, such as
423    pH and flammability.

424    An example to illustrate this procedure is given in Annex 1 (example 1).

425    5.3.2. Quantitative risk characterisation

426    The procedure for the quantitative risk assessment consists of comparing the exposure levels to which
427    the user is exposed or is likely to be exposed with the exposure levels at which no adverse effects are
428    expected to occur. This is generally done by comparing the estimated exposure to the relevant TRV,
429    i.e. calculating the margin of exposure (MOE).

430    The duration of the study from which the TRV is derived should preferably reflect the duration of
431    exposure of the user. The risk assessment of short-term exposure should be based on acute TRVs or, if
432    not available, on sub-acute or sub-chronic TRVs, the latter representing, in general, a worst-case
433    approach. In light of the 3Rs, specific acute studies should not be performed to derive an acute TRV.
434    Instead, the acute TRV should be derived from acute effects observed in other study types, e.g. sub-
435    chronic or developmental toxicity studies. For the risk assessment of long-term exposure, the use of a
436    sub-chronic or chronic TRV can be considered acceptable, depending on the longest duration of user
437    exposure, including exposure due to repeated treatment of the animal.

438    When comparing the estimated exposure to the relevant TRV, the following parameters should be
439    considered:

440•   the intra- and interspecies variation 4;


       4
         To account for uncertainty related to interspecies variation (i.e. extrapolation from animals to humans) a standard factor of x10 is
       used unless there is reliable data to deviate from this.



       Guideline on user safety for pharmaceutical veterinary medicinal products
       EMEA/CVMP/543/03-Rev.2                                                                                                     Page 12/26

第 13 页

441•   the nature and severity of the effect;

442•   the human population to which the exposure information applies;

443•   the differences in exposure (route, duration, frequency);

444•   the dose-response relationship observed;

445•   the overall confidence in the available data.

446    These parameters are used to establish an uncertainty factor, which the MOE will then be compared to.
447    It is generally recognised that the default uncertainty factor (UF) is 100, i.e. an MOE of 100 or higher
448    would be considered acceptable. This value of 100 is the product of two factors of 10, one for
449    interspecies extrapolation and the other for intraspecies (inter-individual) variability. The interspecies
450    uncertainty factor is used for extrapolating the animal derived TRV to an average healthy individual,
451    taking into account that humans may be more sensitive than laboratory animals. The intraspecies
452    factor takes into account susceptible human subpopulations.

453    Where reliable data are available, there may be a case for accepting an MOE other than 100, e.g. if
454    there is a case for accepting that the standard values for inter- and intraspecies variation do not apply.
455    Similarly, the nature of the studies used to determine a TRV will also influence the uncertainty factor.
456    For example, if the TRV is based on a NO(A)EL derived from a human study, then an MOE of 10 could
457    be accepted as no interspecies extrapolation is required. Note that the accepted therapeutic dose used
458    in human medicine does not imply an absence of risk and, therefore, it is generally not acceptable as a
459    TRV.

460    The nature and severity of observed effects also influence risk assessments based on a NO(A)EL. The
461    magnitude of the uncertainty factor can be increased for effects such as non-genotoxic carcinogenicity,
462    neurotoxicity or teratogenicity. Severe adverse effects such as these may require an additional factor
463    of between 2 and 10 and may also be applied only to a specific human population, e.g. pregnant
464    women. For example, the observation of teratogenic effects would warrant an additional uncertainty
465    factor of 5 – 10. If the TRV is a lowest observed (adverse) effect level (LO(A)EL) then an additional
466    factor of 2 - 5 would be required, depending on the dose-response relationship and/or the severity of
467    effects observed.

468    While from a scientific point of view the exposure route of the study from which the TRV is derived
469    should preferably reflect the route of exposure of the user, from a 3Rs point of view the use of existing
470    data is encouraged. To this end, route-to-route extrapolation would need to be employed (see also the
471    Guideline on user safety of topically administered VMPs for more detailed information on route-to-route
472    extrapolation). Also, a difference in duration of the study may be a case for accepting an MOE either
473    higher or lower than 100. With respect to the overall confidence in the available data, it should be
474    noted that, in order to compensate for deficiencies in toxicity data, an additional factor may be
475    required, increasing the acceptable MOE above the default factor of 100.

476    Where appropriate and justified, available toxicological limit values or exposure limit values (e.g. AOEL
477    or other occupational limits, ARfD, ADI) may be used as alternatives to the MOE approach as described
478    above. For some derived reference values (e.g. ADI and ARfD) the level of uncertainty has already
479    been taken into account in its calculation. If sufficient uncertainty factors were applied and the same
480    type of exposure is being assessed, exposure can be directly compared to this reference value. For




       To account for uncertainty related to intraspecies variation (i.e. differences in human susceptibility) a standard factor of x10 is used
       unless there is reliable data to deviate from this.
       When alternative factors are proposed, consideration must be given to the guidance document published by the IPCS/WHO
       (IPCS/WHO, 2005).

       Guideline on user safety for pharmaceutical veterinary medicinal products
       EMEA/CVMP/543/03-Rev.2                                                                                                       Page 13/26

第 14 页

481    example, if the estimated oral exposure is less than the ADI, the risk for the user is considered to be
482    acceptable.

483    With multiple factors influencing the magnitude of the acceptable MOE, adequate justification for each
484    parameter should be provided. The acceptability of the MOE and, thus, the risk to the user will require
485    expert judgement. In the case of a potential risk to the user, risk management options should be
486    proposed and evaluated.

487    An example to illustrate this procedure is given in Annex 1 (example 2).

488    5.4. Risk management

489    Users

490    Some users will have more experience and knowledge of handling and administering VMP to animals
491    than others, such as veterinarians or farmers, and this needs to be acknowledged in the assessment.
492    Similarly, when considering other users who do not administer VMP on a frequent basis, such as pet
493    owners, more detailed risk mitigation measures may be required in order to handle and administer the
494    product safely.

495    Some users may have limited access to personal protective equipment (PPE) and, therefore, if
496    required, there must be advice on what PPE is needed or the PPE has to be provided with the VMP.

497    In the case of users incorporating premixes into feed and users of the medicated feed, consideration
498    should be given to the need for separate advice and warnings for the different types of users (e.g. PPE
499    may be required when incorporating the premix, but not when administering the medicated feed).

500    Risk control options

501    In general, the following options for risk control may be used:

502•   restriction of the distribution, for example, as prescription-only medicine;

503•   specific warnings for groups at risk, for example, sensitised people, pregnant women, or where there
504    are risks to fertility;

505•   restriction of application methods, for example, pour-on instead of spraying or the use of closed
506    delivery systems;

507•   restriction of the field of use, for example, outdoor use only;

508•   modification of the formulation, for example, ready-to-use rather than a concentrate;

509•   modification of packaging, for example, reduced pack size or child-resistant packaging*;

510•   recommendation of measures for the protection of users, for example, general controls like ventilation
511    of rooms, or use of PPE like protective gloves, masks or goggles. The appropriateness, i.e. the inherent
512    efficiency, of these measures should be discussed. For example, the choice of materials should be
513    justified (it is well known that certain substances are able to permeate or penetrate through certain
514    materials, e.g. solvents through latex gloves).

515    *Note: Packaging can be claimed as child-resistant packaging only if it has been demonstrated to be
516    child-resistant in accordance with the European Standard EN14375 for non-reclosable packaging or
517    EN8317 for reclosable packaging.

518    The proposed risk control measures should be evaluated against the following criteria:



       Guideline on user safety for pharmaceutical veterinary medicinal products
       EMEA/CVMP/543/03-Rev.2                                                                          Page 14/26

第 15 页

519•   the extent to which the exposure is reduced by a risk control measure, alone or in combination with
520    other measures, must be large enough to reduce the risk to an acceptable level;

521•   the measure should be practicable, for example, PPE must be readily available to the user, and
522    measures should not hamper the use of the product too much. It is considered unreasonable, for
523    example, to expect a pet-owner to have access to personal protective equipment beyond normal
524    household gloves. Therefore, in exceptional cases, it might be appropriate to provide adequate PPE
525    with the VMP.

526    5.5. Risk communication

527    The warnings and safety measures are communicated via the SPC and package leaflet and should
528    inform the user about the following aspects:

529A. The concerned risk, i.e. the identified hazard

530B. What exposure must be avoided to minimise the concerned risk

531C. How to avoid that exposure

532D. What to do in the event of exposure (if relevant)

533    The following illustrations explain this:

534    Example 1: A liquid product that is administered by the farmer using a spray gun to a flock of sheep,
535    is irritant to the eyes. The warnings in the SPC and on the package leaflet would be:

536    •    This veterinary medicinal product can cause eye irritation. (A)

537    •    Avoid contact with the eyes including hand-to-eye contact. (B)

538    •    Personal protective equipment consisting of protective glasses should be worn when handling the
539         veterinary medicinal product. (C)

540    •    Wash hands after use. (D)

541    •    When the veterinary medicinal product comes into contact with the eyes, rinse immediately with
542         plenty of water. In case irritation persists, seek medical advice immediately and show the package
543         leaflet or the label to the physician. (D)

544    In the A-phrase it is recommended to specify the actual hazard, i.e. in this situation this VMP can
545    cause eye irritation. Other examples could be ‘This veterinary medicinal product can cause sedation.’
546    or ‘This veterinary medicinal product can cause neurotoxicity.’, etc.

547    Example 2: An antibiotic tablet containing a penicillin, that is administered by the pet owner to dogs,
548    and for which hypersensitivity reactions may be expected. The warnings in the SPC and on the
549    package leaflet would be:

550    •    <This veterinary medicinal product> <Penicillins and cephalosporins> may cause hypersensitivity
551         (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins
552         may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these
553         substances may occasionally be serious. (A)

554    •    People with known hypersensitivity to penicillins or cephalosporins should avoid contact with the
555         veterinary medicinal product. (B)

556    •    Handle this veterinary medicinal product with great care to avoid exposure. (C)

557    •    Wash hands after use. (D)

       Guideline on user safety for pharmaceutical veterinary medicinal products
       EMEA/CVMP/543/03-Rev.2                                                                               Page 15/26

第 16 页

558   •    If you develop symptoms following exposure, such as a skin rash, you should seek medical advice
559        and show the package leaflet or the label to the physician. Swelling of the face, lips or eyes or
560        difficulty in breathing are more serious symptoms and require urgent medical attention. (D)

561   The substance(s) that might cause hypersensitivity reactions should always be specified.
562   Example 3: An injectable that is administered by a professional user, and is assessed to be
563   teratogenic, embryo- or foetotoxic. The warnings in the SPC and on the package leaflet would be:

564   •    This veterinary medicinal product may be harmful to the unborn child. (A)

565   •    Avoid contact with the skin and accidental self-injection. (B)

566   •    Pregnant women, or women trying to conceive, should administer the veterinary medicinal product
567        with serious caution to avoid accidental self-injection. (C)

568   •    Personal protective equipment consisting of impervious gloves should be worn when handling the
569        veterinary medicinal product. (C)

570   •    In case of accidental skin exposure, wash hands/exposed skin thoroughly. In case of accidental
571        self-injection, seek medical advice immediately and show the package leaflet or the label to the
572        physician. (D)

573   Note that different risk mitigation measures might be applicable for professional or non-professional
574   users administering the same substance, depending on the formulation of the VMP, the risk
575   characterisation, and also on the level of experience of the user.

576   The user safety warnings should be written and designed to be readable, clear and understandable, in
577   terms that are comprehensible to the general public. The user safety warnings should be justified. User
578   safety warnings should be written in full in the SPC and the package leaflet. In general, the label only
579   contains the information ‘Read the package leaflet before use’.

580   For additional guidance on the presentation of user safety warnings in the product information, the
581   reader is referred to the most recent version of the Quality Review of Documents veterinary product
582   information template.

583   Two worked examples of User Risk Assessments (URAs) are presented in Annex I of this guideline to
584   show a qualitative risk characterisation and a quantitative risk characterisation. Furthermore, a
585   template for a URA is provided in Annex II.

586




      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                           Page 16/26

第 17 页

587   Definitions
       Acceptable daily intake (ADI)             The estimate of the amount of a substance, expressed in terms of
                                                 micrograms or milligrams per kilogram of bodyweight, that can be
                                                 ingested daily over a lifetime without posing any appreciable health
                                                 risk.

       Acute reference dose (ARfD)               An estimate of the exposure to a substance, expressed on a
                                                 body weight basis, that can occur in a period of 24 hours or less
                                                 without adverse effects or harm to the user. The route of
                                                 exposure for which an ARfD applies should be specified.

       Application phase                         The preparation (i.e. opening or accessing the product, mixing
                                                 and/or diluting of concentrates, loading application apparatus) and
                                                 administration of the (prepared) veterinary medicinal product to the
                                                 animal(s), including application by hand or any other dosing
                                                 equipment. This phase can lead to exposure of the person
                                                 administrating the product, as well as of other people who are
                                                 present during the product administration.

       Benchmark Dose                            The Benchmark Dose (BMD) is a dose level, estimated from the
                                                 fitted dose-response curve, associated with a specified change in
                                                 response relative to the control group.

       Exposure                                  Contact with a substance by oral, dermal, parenteral, ocular and/or
                                                 inhalation routes. Exposure in the context of this guideline may be
                                                 short-term (once or for a short time), or long-term (repeated
                                                 exposure for a longer period).

       Exposure assessment                       The process that involves estimating the magnitude, frequency, and
                                                 duration of exposure to a VMP for a specific substance, route of
                                                 exposure and user.

       Exposure route                            The way an agent enters a human or animal after contact (e.g. by
                                                 ingestion, inhalation, or dermal absorption).

       Exposure scenario                         A set of conditions that describe how users may accidentally come
                                                 into contact with a veterinary medicinal product during each
                                                 task/situation associated with its administration to target animals
                                                 when the VMP is used as intended and/or when handling the treated
                                                 animal.

       Foreseeable accidents                     The use of veterinary medicinal products that is not in line with the
                                                 instructions for use or without the consideration of some or all
                                                 common and specific technical, operational and personal protective
                                                 measures (e.g. the over-dosing or inadequate dilution of a
                                                 veterinary medicinal product, common spillage scenarios, use
                                                 without or with non-proper PPE).

       Hazard                                    A biological, chemical or physical agent or situation having the
                                                 potential to cause an adverse effect.

       Hazard identification                     The identification of biological, chemical, and physical agents or
                                                 situations capable of causing adverse effects.


      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                                    Page 17/26

第 18 页

Hazard characterisation                   The qualitative and/or quantitative evaluation of the type and
                                           nature of the inherent property of biological, chemical or physical
                                           agents or situations having the potential to cause adverse effects. A
                                           dose-response assessment should be performed if possible.

Lowest-observed(adverse)                  The lowest administered dose in a study at which (adverse)
effect-level (LO(A)EL)                    effect(s) are observed.

Margin of exposure (MOE)                  The ratio of the TRV to an estimated exposure level.

Non-respirable and respirable             The non-respirable fraction of a substance refers to its airborne
fractions                                 particles that are too large to penetrate deeply into the lungs.
                                           These particles are typically trapped in the upper respiratory tract,
                                           such as the nose, throat, and trachea, and do not reach the gas-
                                           exchange regions of the lungs. These inhalable particles can be up
                                           to 100 micrometers (µm) in diameter.

                                           In contrast, the respirable fraction refers to the portion of airborne
                                           particles small enough to penetrate deep into the lungs, reaching
                                           the alveolar region where gas exchange occurs. These particles are
                                           smaller, typically less than 10 micrometers (µm) in diameter.



No-observed-(adverse-)                    The highest administered dose in a study at which no (adverse)
effect-level (NO(A)EL)                    effect is observed.

Personal protective equipment             PPE refers to specialized clothing or equipment to be worn by
(PPE)                                     individuals to protect themselves from a health risk. Types of PPE
                                           include: eye protection (protective glasses), respiratory protection
                                           (masks), hand protection (gloves), body protection (protective
                                           clothing), foot protection (safety boots).

Risk                                      The probability of an adverse effect and the severity of that effect,
                                           consequential to (a) hazard(s).

Risk analysis                             A process consisting of three components: risk assessment, risk
                                           management and risk communication. These steps follow each
                                           other.

Risk assessment                           A process intended to calculate or estimate the risk to target
                                           animals, users, consumers of animal derived food and to the
                                           environment, including attendant uncertainties, following exposure
                                           to a particular agent.
                                           Risk assessment is a science-based process consisting of the
                                           following four steps:
                                                     (i) Hazard identification
                                                     (ii) Hazard characterisation,
                                                     (iii) Exposure assessment,

                                                     (iv) Risk characterisation.

Risk characterisation                     The qualitative and/or quantitative estimation, including associated
                                           uncertainties, of the probability of occurrence and severity of known
                                           or potential adverse effects in target animals, users, consumers of

Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2                                                                                    Page 18/26

第 19 页

                                                 animal derived food or on the environment based on hazard
                                                 identification, hazard characterisation and exposure assessment.

       Risk communication                        The process of communicating information about risks identified
                                                 during a risk assessment. It aims to inform and educate people
                                                 about potential hazards, their impacts, and the measures that can
                                                 be taken to mitigate the risk.

       Risk management                           The process of evaluating risk control options and, where
                                                 necessary, implementing risk mitigation measures to reduce an
                                                 identified risk to an acceptable level for the user.



       Toxicological reference value             A toxicological index that, when compared to exposure, is used to
       (TRV)                                     quantify a risk for human health. TRVs are established for a given
                                                 critical effect and are specific to a substance, duration of exposure
                                                 and route of exposure (e.g. NOEL, NOAEL, BMDL).

       Uncertainty factor                        A numerical factor applied to a toxicological (pharmacological
                                                 /microbiological) endpoint to allow for uncertainties in risk
                                                 assessment such as intraspecies (extrapolating animal data to
                                                 humans) and interindividual (variation in sensitivity among
                                                 humans) variations, the quality of the data, the severity of the
                                                 response. The factor may be a default value used in the absence of
                                                 specific information on a substance or may be modified in the light
                                                 of specific information.

       User                                      Any person that may come into contact with the veterinary
                                                 medicinal product (VMP) or components of the product before its
                                                 application to the animal (e.g. during storage), during its
                                                 application (e.g. during preparation or administration to the
                                                 animal), and after its application (e.g. through contact with the
                                                 treated animals).
588




      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                                     Page 19/26

第 20 页

589   References
590   •     Guideline on dossier requirements for anticancer medicinal products for dogs and cats
591         (EMA/CVMP/28510/2008).

592   •     Guideline on user safety of topically administered veterinary medicinal products
593         (EMA/CVMP/SWP/721059/2014).

594   •     Guideline on user safety for immunological veterinary medicinal products
595         (EMA/CVMP/IWP/54533/2006 Rev.1).

596   •     Guideline on pharmaceutical fixed combination products (EMEA/CVMP/83804/2005).

597   •     IPCS/WHO (2005). Chemical-specific adjustment factors for interspecies differences and human
598         variability: Guidance document for use of data in dose/concentration-response assessment. IPCS
599         harmonization project document no. 2. World Health Organization, Geneva, Switzerland.
600         https://www.who.int/publications/i/item/9241546786

601   •     Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on
602         veterinary medicinal products and repealing Directive 2001/82/EC.

603   •     Reflection paper on providing an overview of the current regulatory testing requirements for
604         veterinary medicinal products and opportunities for implementation of the 3Rs,
605         (EMA/CHMP/CVMP/3Rs/164002/2016).

606   •     VICH GL32: Studies to evaluate the safety of residues of veterinary drugs in human food:
607         Developmental toxicity testing (CVMP/VICH/485/02).


608   Abbreviations
609   ADI                 Acceptable Daily Intake

610   AOEL                Acceptable Occupational Exposure Limit

611   ARfD                Acute Reference Dose

612   BMD(L)              Benchmark Dose (lower confidence limit)

613   EU                  European Union

614   IPCS                International Program on Chemical Safety

615   LOAEL               Lowest Observed Adverse Effect Level

616   MA                  Marketing Authorisation

617   MOE                 Margin of Exposure

618   NOAEL               No Observed Adverse Effect Level

619   OECD                Organisation for Economic Co-operation and Development

620   PPE                 Personal Protective Equipment

621   SPC                 Summary of Product Characteristics

622   TRV                 Toxicological Reference Value

623   VMP                 Veterinary Medicinal Product


      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                           Page 20/26

第 21 页

624   WHO                 World Health Organisation


625   Annex 1
626   Worked examples

627   Two worked examples of User Risk Assessments (URAs) are presented below to show a qualitative risk
628   characterisation and a quantitative risk characterisation.

629   The examples are provided to assist in understanding how URAs are conducted and do not aim to
630   provide comprehensive URAs addressing all aspects of these assessments. The two examples below
631   are for guidance purposes only and should not be regarded as exhaustive. Other concerns (e.g.
632   systemic toxicity) may need to be addressed, depending on the routes of exposure and the toxicity
633   profiles.

634   The examples are presented using the template (given in Annex 2). All URAs should include the four
635   aspects of risk assessment, namely hazard identification, hazard characterisation, exposure
636   assessment and risk characterisation, as given in this guideline and as presented in the template. It
637   may be noted that hazard identification and hazard characterisation are considered together in this
638   guideline as they are intrinsically linked.

639   Example 1: URA based on a qualitative risk characterisation

640   Brief description of product: An anthelmintic for oral administration which is provided as a suspension
641   for use in drinking water for pigs. The package size is a 4-liter plastic container, and a separate
642   dispenser (measuring device) is provided.

643   Note: Only the qualitative risk characterisation is described in this example. Adverse effects which
644   require quantitative risk assessment are not considered.

645   User Risk Assessment

646   1.        Hazard Identification and Characterisation

647   Appraisal of the toxicity and hazards.

648   Pharmacology and toxicology studies, including studies on irritation and sensitisation, are presented in
649   section 3A2-3A4, though a summary with conclusions should be provided in section 3A5 URA.

650   1.1       Toxicity data on active substance(s):

651   The following was concluded for the active substance in regard to local toxicity:

652   •     No skin or eye irritation studies are available for the active substance.

653   •     Observations in humans indicate skin irritation following dermal contact with the active substance.

654   1.2       Toxicity data on formulation:

655   The following was concluded for the formulation in regard to local toxicity:

656   •     A skin irritation study with the final formulation showed mild irritation.

657   •     An eye irritation study showed no signs of irritation.

658   •     A skin sensitisation study showed no evidence of sensitisation.


      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                            Page 21/26

第 22 页

659   2.        Exposure

660   Appraisal of the exposure.

661   2.1       Precise identification of the product

662   •     The product is a suspension presented in a 4-litre plastic container. A separate dispenser is
663         provided for dosing.

664   •     The VMP is to be administered via drinking water to pigs.

665   2.2       Exposure scenarios

666   •     Exposure may occur during the application phase (when added to the drinking water and
667         administered to the animals) or the post-application phase (during cleaning of the dispenser and
668         disposal activities).

669   2.3       Type of user

670   •     The VMP will be applied by farmers. Children are not expected to have access to the VMP as this
671         VMP is to be used by professional users and kept in a professional environment.

672   2.4       Routes of exposure

673   •     The main routes of exposure are dermal exposure from accidental spillage when handling the
674         product and when cleaning the dispenser after dosing. Exposure of the eyes may also be possible
675         through splashes when adding the VMP to the drinking water.

676   2.5       Magnitude, duration and frequency of exposure

677   •     Under normal conditions of use, skin and eye exposure is possible every time the VMP is
678         administered, i.e. when added to the drinking water due to accidental spillage and/or splashes.
679         Skin exposure is very likely when cleaning the dispenser.

680         Note that, as only the qualitative risk assessment is described in this example, no exposure level is
681         estimated.

682   3.        Risk characterisation

683   3.1       Qualitative risk characterisation

684   •     The risks following eye exposure are considered negligible, because adverse effects to the eyes are
685         not expected in view of the negative eye irritation study with the formulation.

686   •     A skin irritation study with the final formulation showed a mild irritating effect. Irritation of the skin
687         in humans was observed after dermal contact with the active substance.

688   •     The risk for skin sensitisation is low in view of the negative skin sensitisation study.

689   3.2       Quantitative risk characterisation

690   Quantitative risk not determined in this example.

691   4         Risk Management.

692   •     Risk mitigation measures should be in place to address the possibility of irritation after accidental
693         skin exposure when preparing the medicated drinking water and cleaning the dispenser.




      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                                Page 22/26

第 23 页

694   5         Risk Communication.

695   The user warnings on the SPC and package leaflet are 5:

696   •    This veterinary medicinal product may be irritating to the skin. (A)

697   •    Avoid skin contact. (B)

698   •    Personal protective equipment consisting of impervious gloves should be worn when handling the
699        veterinary medicinal product and cleaning the measuring device. (C)

700   •    Wash hands after use. (D)

701   •    In case of accidental spillage onto the skin, immediately rinse with plenty of water. Remove
702        contaminated clothing after spillage. If irritation persists, seek medical advice and show the label or
703        package leaflet to the physician. (D)

704   Example 2: URA based on a quantitative risk characterisation

705   Brief description of product: A VMP for oral administration to dogs by a pet owner at home. There are
706   two strengths of coated tablets, 20 mg and 50 mg.

707   Only the quantitative risk characterisation is described in this example.

708   User Risk Assessment

709   1.        Hazard Identification and Characterisation

710   Appraisal of the toxicity and hazards.
711   Pharmacology and toxicology studies are presented in section 3A2-3A4, though a summary with
712   conclusions on the relevant (lowest) TRVs should be provided in section 3A5 URA.

713   1.1       Toxicity data on active substance(s).

714   The following was concluded for the active substance:

715   •     NOAEL = 10 mg/kg, based on a 14-day toxicity study in dogs, where dizziness and low blood
716         pressure were observed at higher doses.

717   1.2       Toxicity data on formulation.

718   No toxicity studies using the formulation are presented. The systemic toxicity is determined by the
719   active substance.

720   2.        Exposure

721   Appraisal of the exposure.

722   2.1        Precise identification of the product

723   •     The VMP is presented in cartons containing 10 blister strips, each strip containing 10 coated tablets
724         of 20 mg or 50 mg.

725   •     Tablets are administered to the animals once or twice a day.



      5 The capital letters in brackets correspond to those used in section 5.5. of this guideline



      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                             Page 23/26

第 24 页

726   2.2       Exposure scenarios.

727   •     Exposure may occur during the pre-administration phase (storage, as the VMP is stored at home)
728         and during the administration phase (when administered to the animal).

729   2.3       Type of user

730   •     The VMP will be administered by dog owners. Children may get access to the VMP if not properly
731         stored.

732   2.4       Routes of exposure

733   •     The main routes of exposure are dermal exposure from handling the tablets or accidental ingestion
734         of the tablets by a child.

735   2.5       Magnitude, duration and frequency of exposure

736   •     When handling the tablet, skin exposure is estimated to be negligible in view of the coating on the
737         tablet. Accidental ingestion by a child in the home needs to be addressed. A young child of
738         approximately 12.5 kg body weight (bw) ingesting 1 tablet is considered to be a reasonable worst-
739         case scenario, as it is assumed that a young child may be left unattended for a short time and the
740         VMP is packed in a blister.

741   •     Accidental ingestion of one 50 mg tablet in a single exposure would give a dose of 50 mg or 4
742         mg/kg bw when considering the bw of 12.5 kg.

743   3.        Risk characterisation

744   3.1       Qualitative risk characterisation

745   - Qualitative risk is not determined in this example.

746   3.2       Quantitative risk characterisation

747   Based on the exposure of 4 mg/kg bw as a result of the ingestion of one 50 mg tablet by a 12.5 kg
748   child, and considering the NOAEL of 10 mg/kg, the MOE is 10/4= 2.5. This MOE is lower than 100 (the
749   factor needed to take account of intra- and interspecies variation), it is therefore considered that risk
750   mitigation measures should be in place.

751   4         Risk Management

752   •     Because of the risk of accidental ingestion, risk mitigation measures should be in place to prevent
753         children from accidentally ingesting tablets.

754   5         Risk Communication

755   The user warnings on the SPC and package leaflet are:

756
757   •     This veterinary medicinal product may cause dizziness or low blood pressure. (A)

758   •     Avoid accidental ingestion. (B)

759   •     Care should be taken to prevent accidental ingestion by children. In order to prevent children from
760         accessing the product, do not remove tablets from the blister until ready to administer to the


      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                              Page 24/26

第 25 页

761        animal. Tablets should be administered and stored (in the original packaging) out of the sight and
762        reach of children. (C)

763   •    In case of accidental ingestion, seek medical advice immediately and show the package leaflet or
764        the label to the physician. (D)

765




      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                         Page 25/26

第 26 页

766   Annex 2

767   Template for a user risk assessment

768   The following template can be used to present a user risk assessment, however it should be noted that
769   all the headings may not be needed and can be deleted as required.
770   User Risk Assessment

771   1.        Hazard Identification and Characterisation

772   1.1       Toxicity data on active substance(s)

773   1.2       Toxicity data on formulation

774   2.        Exposure assessment

775   2.1       Precise identification of the product

776   2.2       Exposure scenarios

777   2.3       Type of user

778   2.4       Routes of exposure

779   2.5       Components of a product to which the user is exposed

780   2.6       Magnitude, duration and frequency of exposure

781   3.        Risk characterisation

782   3.1       Qualitative risk characterisation

783   3.2       Quantitative risk characterisation

784   4         Risk Management

785   5         Risk Communication




      Guideline on user safety for pharmaceutical veterinary medicinal products
      EMEA/CVMP/543/03-Rev.2                                                                      Page 26/26

来源:EMA 官方医药监管信息 · ema.europa.eu